Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.88 USD
+0.04 (2.17%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.87 -0.01 (-0.53%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AADI 1.88 +0.04(2.17%)
Will AADI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AADI
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
Other News for AADI
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
Aadi Bioscience announces new nonclinical data from nab-sirolimus trial
H.C. Wainwright Sticks to Its Hold Rating for Aadi Bioscience (AADI)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Aadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...